Published in J Clin Oncol on April 20, 2010
Estimation of renal cell carcinoma treatment effects from disease progression modeling. Clin Pharmacol Ther (2012) 1.55
Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. Blood (2010) 1.33
Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology (2011) 1.25
Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst (2011) 1.17
Resampling phase III data to assess phase II trial designs and endpoints. Clin Cancer Res (2012) 1.11
More randomization in phase II trials: necessary but not sufficient. J Natl Cancer Inst (2011) 1.03
Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741. Oncologist (2011) 0.91
Designing phase II trials in cancer: a systematic review and guidance. Br J Cancer (2011) 0.91
Randomized phase II trials: misleading and unreliable. J Clin Oncol (2010) 0.88
Do single-arm trials have a role in drug development plans incorporating randomised trials? Pharm Stat (2015) 0.84
Latest developments in the treatment of melanoma: 'a penicillin moment for cancer'? J R Soc Med (2011) 0.80
Challenges of clinical trial design for targeted agents against pediatric leukemias. Front Oncol (2015) 0.79
ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers. ESMO Open (2016) 0.78
Precision medicine needs randomized clinical trials. Nat Rev Clin Oncol (2017) 0.77
Randomized phase II clinical trials. J Biopharm Stat (2014) 0.75
Statistical evaluation of the use of concurrent controls in treatment screening studies. Clin Transl Sci (2013) 0.75
Mixed response and time-to-event endpoints for multistage single-arm phase II design. Trials (2015) 0.75
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35
Cetuximab for the treatment of colorectal cancer. N Engl J Med (2007) 13.39
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med (2003) 12.17
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol (2008) 7.89
Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol (2006) 7.21
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol (2004) 7.04
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol (2010) 6.87
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA (2010) 6.65
Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol (2008) 6.42
Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol (2005) 6.38
Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. JAMA (2002) 6.21
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol (2005) 6.20
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol (2009) 5.42
Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol (2010) 5.07
Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA (2010) 5.04
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum (2002) 4.69
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol (2011) 4.56
Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst (2009) 4.36
Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum (2002) 4.23
Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol (2007) 4.14
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst (2011) 4.08
Tumour heterogeneity in the clinic. Nature (2013) 3.92
Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol (2013) 3.76
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol (2004) 3.67
Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev (2010) 3.67
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol (2009) 3.61
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol (2008) 3.49
Predictors of infection in rheumatoid arthritis. Arthritis Rheum (2002) 3.47
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist (2007) 3.42
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol (2009) 3.38
The statins as anticancer agents. Clin Cancer Res (2003) 3.36
Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol (2005) 3.34
Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. J Clin Oncol (2006) 3.31
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol (2014) 3.20
Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol (2013) 3.18
Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol (2007) 3.16
Measured and estimated GFR in healthy potential kidney donors. Am J Kidney Dis (2004) 3.11
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol (2012) 3.02
Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol (2007) 3.00
Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol (2005) 2.83
Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol (2006) 2.66
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol (2011) 2.57
Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review. J Natl Cancer Inst (2012) 2.57
Medication reconciliation at hospital discharge: evaluating discrepancies. Ann Pharmacother (2008) 2.57
Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer (2008) 2.55
Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol (2005) 2.52
Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy. Eur J Haematol (2005) 2.47
Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer. J Natl Cancer Inst (2012) 2.46
Impact of wait times on survival for women with uterine cancer. J Clin Oncol (2013) 2.45
End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol (2007) 2.41
Colorectal cancer: how emerging molecular understanding affects treatment decisions. Oncology (Williston Park) (2014) 2.21
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol (2014) 2.17
Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. J Natl Cancer Inst (2009) 2.16
Nasopharyngeal carcinoma: the next challenges. Eur J Cancer (2010) 2.04
Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist (2009) 1.99
Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol (2012) 1.95
Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res (2010) 1.93
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol (2007) 1.91
Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. J Natl Cancer Inst (2013) 1.90
The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist (2007) 1.89
Biomarkers and surrogate end points--the challenge of statistical validation. Nat Rev Clin Oncol (2010) 1.87
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res (2010) 1.85
Current issues in adjuvant treatment of stage II colon cancer. Ann Surg Oncol (2006) 1.85
Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer (2006) 1.83
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res (2003) 1.82
Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. J Clin Oncol (2008) 1.82
Designing transformative clinical trials in the cancer genome era. J Clin Oncol (2013) 1.79
Dermopathy of Graves' disease (pretibial myxedema): long-term outcome. J Clin Endocrinol Metab (2002) 1.73
Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J Clin Oncol (2003) 1.71
First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting. J Hematol Oncol (2008) 1.70
Cancer genomics: technology, discovery, and translation. J Clin Oncol (2012) 1.70
Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. J Clin Oncol (2005) 1.69
Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience. Eur Urol (2010) 1.67
Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol (2008) 1.65
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol (2012) 1.64
Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination. Clin Cancer Res (2006) 1.63
Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol (2005) 1.63
Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology (2010) 1.62
Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol (2010) 1.61
The position of the polycystic kidney disease 1 (PKD1) gene mutation correlates with the severity of renal disease. J Am Soc Nephrol (2002) 1.60
Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res (2006) 1.58
Pharmacist medication assessments in a surgical preadmission clinic. Arch Intern Med (2007) 1.57
Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther (2005) 1.57
The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. Cancer (2011) 1.55
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst (2013) 1.54
Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol (2007) 1.53
Systematic review of statistical methods used in molecular marker studies in cancer. Cancer (2008) 1.53
Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol (2005) 1.52